AC Immune’s Post

📢 Upcoming Industry Symposium Alert! 📢 Join us on Wednesday, March 6, at 8:40 AM (GMT) in Auditorium I for an insightful industry symposium that promises to deepen your understanding and spark engaging discussions. 🔍 Focus Area: We will be diving deep into the latest research on alpha-synuclein targeting approaches, which are at the forefront of innovation in diagnostics and therapeutics. 🎯 What to Expect? • Get first-hand insights from leading experts in the field. • Explore cutting-edge diagnostic and therapeutic strategies. • Network with professionals and thought leaders passionate about neurological research. Don’t miss this opportunity to stay ahead of the curve in the dynamic landscape of neurological research. Let’s explore the future of diagnostics and therapeutics together! #IndustrySymposium #AlphaSynuclein #Diagnostics #Therapeutics #precisionmedicine #parkinsonsdisease #NeurologyResearch

📢 We are excited to announce the launch of our brand-new website! At PLL Therapeutics we are developing a groundbreaking polypeptide delivery platform to treat the root causes of autoimmune and neurodegenerative diseases with the focus on restoring gut permeability. Our first indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. To date there are few studies on the disease's prevalence, however a report published in Nature Communications in 2016 shows the number of ALS cases across the globe increasing from 222,801 in 2015 to 376,674 in 2040, representing an increase of 69%. Therefore, it is essential for us to find new and innovative therapies to treat the disease and improve the quality of life for patients across the globe. Watch this space for upcoming news! 💻 Visit www.pll-therapeutics.com to learn more about our mission to treat ALS #ALS #biotech #diagnostics #autoimmune, #microbiome #neurodegenerative #innovation, #ALSawareness #gutbrainaxis #immunomodulation #inflammation

"The more we did, the more we saw we were actually changing paradigms." The latest op-ed from Jürgen Eckhardt discusses the revolutionary potential of CAR-T #celltherapy in treating #autoimmunediseases as recent studies have shown remarkable results for patients with severe autoimmune conditions like #lupus. One inspiring case involved a young woman with a critical case of lupus who had no other treatment options. After receiving CAR T-cell therapy, she not only survived but thrived, passing the 1000-day mark of remission and reclaiming her life. Such stories underscore the transformative potential of CAR T-cell therapy, which was initially developed for blood cancers but now shows promise for autoimmune diseases. Our portfolio company, Capstan Therapeutics, is pioneering in vivo CAR-T therapies, which aim to simplify and scale this potentially revolutionary treatment. By leveraging #mRNA technology, Capstan's approach could enable the patient's body to produce CAR T cells directly, making the treatment more accessible and efficient. Read more on this exciting journey towards better, more effective treatments for autoimmune diseases and beyond: https://lnkd.in/gbVtSEGM

Today is #RareDiseaseDay! DYK that 36 million people in the EU live with a rare disease, and that 70% of rare diseases start in childhood? Take a look at some of IMI and IHI's projects to develop new treatments for #RareDiseases: ✔ EU-PEARL - EU Patient- cEntric clinicAl tRial pLatforms developed a new way of conducting clinical trials to speed up drug development for people with rare tumour disorders (amongst other disease types) ✔ STOPFOP is trialling the cancer drug saracatinib to see if it could be used to treat people with a disease that turns muscle into bone ✔ Screen4Care plans to accelerate rare disease diagnosis by advancing #NewbornScreening and digital technologies ✔ PaLaDIn is a new IHI project that is developing a data platform to collect #RealWorldData on people with rare neuromuscular diseases to accelerate new drug development. Find out more about the projects on our website: www.ihi.europa.eu

Daniele Noviello presents this study focusing on the impact of different biological therapies on a subset of Th17 cells, known as pathogenic Th17 (pTh17) cells, in patients with Crohn’s disease. The research demonstrates that Risankizumab, unlike Ustekinumab or Vedolizumab, effectively downregulates IL-23-induced mucosal pTh17 cells in these patients. #Crohns #ECCO24 #Risankizumab

One of the best aspects of clinical research is that when it goes beyond answering research questions: In Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC). Analysis did not stop in overall survival for all subgroups. Analysis answers the important question: What happened to those patients who had disease progression on STRIDE protocol ? They had the worst prognosis and worst overall survival, even after stopping treatment and having new subsequent lines. this means that the next step is to investigate the causes of failure for those patients who have resistant HCC clones to many lines of treatment. Lorenza Rimassa : thanks for your fruitful interactive discussion #HCC #STRIDE #Durvalumab #HIMALAYA

Daniele Noviello presents this study focusing on the impact of different biological therapies on a subset of Th17 cells, known as pathogenic Th17 (pTh17) cells, in patients with Crohn’s disease. The research demonstrates that Risankizumab, unlike Ustekinumab or Vedolizumab, effectively downregulates IL-23-induced mucosal pTh17 cells in these patients. #Crohns #ECCO24 #Risankizumab

Daniele Noviello presents this study focusing on the impact of different biological therapies on a subset of Th17 cells, known as pathogenic Th17 (pTh17) cells, in patients with Crohn’s disease. The research demonstrates that Risankizumab, unlike Ustekinumab or Vedolizumab, effectively downregulates IL-23-induced mucosal pTh17 cells in these patients. #Crohns #ECCO24 #Risankizumab

Read BioStock - Connecting Innovation and Capital's interview with our CEO, Ellen Donnelly, including comments on the first quarter, the recent financing round, and the upcoming interim analysis in the ongoing FALCON study: "I am confident that we have designed a study that will properly test the safety and efficacy of KL1333 in patients with primary mitochondrial disease." Read the full interview by following the link below: #mitochondrialdisease #mito #q1 #drugdevelopment https://lnkd.in/d4CqS3yF

Join Dr. Timothy Miller today for his #AAIC24 session titled, Antisense Oligonucleotide Therapeutics for Neurodegenerative Diseases.    Dr. Miller is a co-recipient of the 2023 #RainwaterPrize for Outstanding Innovation in Neurodegenerative Research for his decades of work toward uncovering effective therapies for diseases including amyotrophic lateral sclerosis (ALS) and primary tauopathies.    See how Dr. Miller’s work is propelling tau research forward: https://lnkd.in/enfhmCvd